Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(+)-catechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
(+)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
(-)-epigallocatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
(-)-epigallocatechin-3-O-gallate + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
(R)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene + S-adenosyl-L-methionine
?
-
-
-
-
?
(R)-3,4-dihydroxymethamphetamine + S-adenosyl-L-methionine
?
-
-
-
-
?
(R)-N-ethyl-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
?
-
-
-
-
?
(S)-1,2-dihydroxy-4-[2-(methylamino)butyl]benzene + S-adenosyl-L-methionine
?
-
-
-
-
?
(S)-3,4-dihydroxymethamphetamine + S-adenosyl-L-methionine
?
-
-
-
-
?
(S)-N-ethyl-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
?
-
-
-
-
?
1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
2-hydroxyestradiol 3-methyl ether + S-adenosyl-L-homocysteine
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
2-methoxyestradiol + S-adenosyl-L-homocysteine
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 2-methoxyestradiol + 2-hydroxy-3-methoxyestradiol
-
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
2-hydroxyestradiol-17beta + S-adenosyl-L-methionine
2-methoxyestradiol-17beta + 2-hydroxyestradiol-17beta methyl ether + S-adenosyl-L-homocysteine
-
-
-
?
2-hydroxyestrogen + S-adenosyl-L-methionine
2-methoxyestrogen + S-adenosyl-L-homocysteine
-
-
-
-
?
2-hydroxyestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
the production of 2-methoxyestrone in cultures treated with 2-hydroxyestrone is approximately 2fold that of 4-methoxyestrone in cultures treated with 4-hydroxyestrone
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
3-hydroxy-4-methoxybenzoic acid + S-adenosyl-L-homocysteine
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
3,4-dihydroxymandelic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxyphenylacetic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
3,5-dinitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3-hydroxytyramine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-methoxytyramine
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
(17beta)-estra-1(10),2,4-triene-3,4,17-triol + S-adenosyl-L-homocysteine + ?
-
MCF-10F cells oxidize 4-hydroxyestradiol to estrone (estradiol)-3,4-quinones, which react with DNA to form the depurinating N3Ade and N7Gua adducts
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
4-hydroxyestrogen + S-adenosyl-L-methionine
4-methoxyestrogen + S-adenosyl-L-homocysteine
-
-
-
-
?
4-hydroxyestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
6,7-dihydroxycoumarin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
adrenaline + S-adenosyl-L-methionine
methanephrine + S-adenosyl-L-homocysteine
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
aesculetin + S-adenosyl-L-methionine
scopoletin + S-adenosyl-L-homocysteine
-
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
caffeic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
catechol + S-adenosyl-L-methionine
guaiacol + S-adenosyl-L-homocysteine
catechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
catecholestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
catecholestrone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
DL-3,4-dihydroxyamphetamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
DL-3,4-dihydroxyephedrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dobutamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopamine
-
-
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
epinine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
esculetin + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
esculetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
fisetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
homoprotocatechuic acid + S-adenosyl-L-methionine
?
-
-
-
-
?
isoetharine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
isoproterenol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
L-dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyl-L-dopa
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
noradrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
p-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
procyanidin dimer B1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin dimer B2 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin dimer B3 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin dimer B4 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin dimer B5 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin dimer B7 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
procyanidin trimer C1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
protocatechualdehyde + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
protocatechuic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
protocatechuic aldehyde + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
17% of the activity with catechol
-
-
?
quercetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
S-adenosyl-L-methionine + (3,4-dihydroxyphenyl)acetic acid
S-adenosyl-L-homocysteine + (4-hydroxy-3-methoxyphenyl)acetic acid + (3-hydroxy-4-methoxyphenyl)acetic acid
-
-
-
?
S-adenosyl-L-methionine + 1,2-dihydroxyphenanthrene
S-adenosyl-L-homocysteine + 1-methoxy-2-hydroxyphenanthrene + 1-methoxy-2-hydroxyphenanthrene
-
-
-
-
?
S-adenosyl-L-methionine + 1-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 1-hydroxypyrene
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 2,3-dihydroxybenzaldehyde
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 2,3-dihydroxynaphthalene
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 2-(1-thienyl)ethyl-3,4-dihydroxybenzylcyano acetate
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + 3,4-dihydroxyacetophenone
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzaldehyde
S-adenosyl-L-homocysteine + 4-hydroxy-3-methoxybenzaldehyde + 3-hydroxy-4-methoxybenzaldehyde
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid
S-adenosyl-L-homocysteine + 4-hydroxy-3-methoxybenzoic acid + 3-hydroxy-4-methoxybenzoic acid
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxybenzoic acid ethyl ester
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxymandelic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxyphenylacetic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxyphenylglycol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3-fluorocatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3-methoxy-5-bromocatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 3-methoxycatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-chlorocatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyequilenin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + 4-isopropylcatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-methylcatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-nitrobenzene-1,2-diol
S-adenosyl-L-homocysteine + 2-methoxy-4-nitrophenol + 2-methoxy-5-nitrophenol
-
-
-
?
S-adenosyl-L-methionine + 4-nitrocatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-tert-butyl-5-methoxycatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 4-tert-butylcatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 5-hydroxydopamine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 6-hydroxydopa
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + 6-hydroxydopamine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
S-adenosyl-L-methionine + a catechol
S-adenosyl-L-homocysteine + a guaiacol
-
-
-
?
S-adenosyl-L-methionine + adrenaline
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + anthrarobin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + carbidopa
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + catechin
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + catechol
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + catecholamine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + chlorogenic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + dihydrexidine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + dobutamine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + 3-methoxytyramine
-
-
-
-
r
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + 3-O-methyldopamine
-
-
-
?
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + epicatechin
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + epicatechin gallate
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin-3-gallate
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + metanephrine
-
-
-
-
?
S-adenosyl-L-methionine + esculetin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + esculetin
S-adenosyl-L-homocysteine + scopoletin
S-adenosyl-L-methionine + ethyl-3,4-dihydroxybenzylcyanoacetate
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + fisetin
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + gallic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + isoproterenol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + levodopa
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + methyl gallate
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + noradrenaline
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
S-adenosyl-L-methionine + pyrene
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + pyrogallol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + quercetin
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + R-salsolinol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + rosmarinic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + salsoline
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + salsoline-1-carboxylic acid
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + scopoletin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + SKF38393
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + tetrachlorocatechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
salvianolic acid B + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
tolcapone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
additional information
?
-
(+)-catechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, 3'-O-methyl derivatives are consistently the main metabolites, meta/para ratio of the metabolites is approximately 25:1
-
?
(+)-catechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, 3'-O-methyl derivatives are consistently the main metabolites, meta/para ratio of the metabolites is approximately 25:1
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, the meta/para ratio of the metabolites is approximately 6:1
-
?
(-)-epicatechin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
3'-O-methyl derivatives are consistently the main metabolites, the meta/para ratio of the metabolites is approximately 6:1
-
?
(-)-epigallocatechin-3-O-gallate + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
(-)-epigallocatechin-3-O-gallate + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
poor substrate for methylation
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
MB-COMT methylates both 2-hydroxyestradiol and 4-hydroxyestradiol at comparable rates
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
S-COMT methylates 2-hydroxyestradiol roughly twice as fast as it methylates 4-hydroxyestradiol
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
2-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
-
-
the meta/para ratio of the metabolites is approximately 4.5
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
4-hydroxy-3-methoxybenzoic acid + S-adenosyl-L-homocysteine
-
-
the meta/para ratio of the metabolites is approximately 4.5
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxybenzoic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxyphenylacetic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
3,4-dihydroxyphenylacetic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
in the mammary gland, catechol estrogens are predominately inactivated by catechol-O-methyltransferase. in the isoflavone-induced. The estrogen receptor is involved in the down-regulation of COMT expression
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
MB-COMT methylates both 2-hydroxyestradiol and 4-hydroxyestradiol at comparable rates
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
S-COMT methylates 2-hydroxyestradiol roughly twice as fast as it methylates 4-hydroxyestradiol
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
?
4-hydroxyestradiol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
4-nitrocatechol + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
6,7-dihydroxycoumarin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
6,7-dihydroxycoumarin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
adrenaline + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
benzene-1,2-diol + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
?
caffeic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
caffeic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
caffeic acid + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
catechol + S-adenosyl-L-methionine
guaiacol + S-adenosyl-L-homocysteine
-
-
-
-
?
catechol + S-adenosyl-L-methionine
guaiacol + S-adenosyl-L-homocysteine
-
-
-
-
?
catechol + S-adenosyl-L-methionine
guaiacol + S-adenosyl-L-homocysteine
-
-
-
-
?
dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
dopamine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
membrane-bound enzyme form MB-COMT
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
soluble enzyme form S-COMT
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
epinephrine + S-adenosyl-L-methionine
metanephrine + S-adenosyl-L-homocysteine
-
-
-
?
fisetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
fisetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
? + S-adenosyl-L-homocysteine
-
-
-
?
L-dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyl-L-dopa
-
-
-
-
?
L-dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyl-L-dopa
-
-
-
-
?
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
-
-
-
-
?
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
-
-
-
-
?
L-Dopa + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + 3-O-methyldopa
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
norepinephrine + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + normetanephrine
-
-
-
-
?
procyanidin dimer B1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B2 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B2 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B3 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B3 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B4 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B4 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B5 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B5 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B7 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin dimer B7 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated and dimethylated dimeric metabolites
-
?
procyanidin trimer C1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated, dimethylated, and trimethylated C1 metabolites
-
?
procyanidin trimer C1 + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
flavanyl units of procyanidins are methylated consecutively, leading to monomethylated, dimethylated, and trimethylated C1 metabolites
-
?
quercetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
quercetin + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
S-adenosyl-L-homocysteine + 4',4''-di-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 2-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 3,4-dihydroxy-L-Phe
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 4-hydroxyestradiol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
-
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
-
-
-
-
?
S-adenosyl-L-methionine + a catechol
?
-
-
-
-
?
S-adenosyl-L-methionine + catechin
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + catechin
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
S-adenosyl-L-methionine + catechin
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
S-adenosyl-L-methionine + catechol
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + catechol
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + dopamine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + epicatechin
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + epicatechin
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
S-adenosyl-L-methionine + epicatechin
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + epigallocatechin gallate
S-adenosyl-L-homocysteine + 4''-O-methyl epigallocatechin gallate
-
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + epinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + esculetin
S-adenosyl-L-homocysteine + scopoletin
-
-
-
?
S-adenosyl-L-methionine + esculetin
S-adenosyl-L-homocysteine + scopoletin
-
-
-
?
S-adenosyl-L-methionine + fisetin
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
S-adenosyl-L-methionine + fisetin
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + L-Dopa
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + norepinephrine
S-adenosyl-L-homocysteine + ?
-
-
-
?
S-adenosyl-L-methionine + quercetin
S-adenosyl-L-homocysteine + ?
-
membrane-bound enzyme form MB-COMT
-
-
?
S-adenosyl-L-methionine + quercetin
S-adenosyl-L-homocysteine + ?
-
soluble enzyme form S-COMT
-
-
?
tolcapone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
inhibitor of isoform MB-COMT, substrate of isoform S-COMT
-
-
?
tolcapone + S-adenosyl-L-methionine
S-adenosyl-L-homocysteine + ?
-
substrate of both isoform S-COMT and isoform MB-COMT
-
-
?
additional information
?
-
-
not: monophenols
-
-
?
additional information
?
-
-
activity in cells expressing norepinephrine transporter
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
comparison of wild type and variant isoforms and implications for estrogen levels
-
-
?
additional information
?
-
-
physiological role is the inactivation of catecholamine hormones and neurotransmitters as well as detoxification of a variety of xenobiotic amines and drugs
-
-
?
additional information
?
-
-
key enzyme in the elemination of dopamine in the prefrontal cortex of the human brain. Genetic variation in COMT gene (MIM 116790) is associated with altered prefrontal cortex function and higher risk for schizophrenia. A common single-nucleotide polymorphism within COMT, Val158Met, significantly affects protein abundance and enzyme activity but not mRNA expression levels. Val is a predominant factor that determines higher COMT activity in the prefrontal cortex, which presumably leads to lower synaptic dopamine levels and relatively deleterious prefrontal function
-
-
?
additional information
?
-
-
the enzyme plays an important role in the inactivation potentially genotoxic catechol estrogens
-
-
?
additional information
?
-
increased COMT enzyme activity in transgenic mice overexpressing a human COMT-Val polymorphism (Val-tg mice) results in disrupted attentional set-shifting abilities, and impaired working and recognition memory, but blunted stress responses and pain sensitivity. COMT disruption improves working memory, but increased stress responses and pain sensitivity. The COMT gene has a critical role in an apparent evolutionary trade-off between cognitive and affective functions
-
-
?
additional information
?
-
-
increased COMT enzyme activity in transgenic mice overexpressing a human COMT-Val polymorphism (Val-tg mice) results in disrupted attentional set-shifting abilities, and impaired working and recognition memory, but blunted stress responses and pain sensitivity. COMT disruption improves working memory, but increased stress responses and pain sensitivity. The COMT gene has a critical role in an apparent evolutionary trade-off between cognitive and affective functions
-
-
?
additional information
?
-
-
prepulse inhibition of the startle reflex depends on the catechol O-methyltransferase Val158Met gene polymorphism
-
-
?
additional information
?
-
-
degree and position of methylation depend clearly on the three-dimensional structure of the entire substrate molecule
-
-
?
additional information
?
-
-
While homozygous catechol-O-methyltransferase deletion results in improvement in spatial learning/working memory with little effect on social behavior, heterozygous deletion results in impairment of recognition memory. Catechol-O-methyltransferase and neuregulin-1 may influence, respectively, primarily cognitive and social endophenotypes of the overall schizophrenia syndrome
-
-
?
additional information
?
-
-
constitutive enzyme may play an important role in detoxification of polycyclic aromatic hydrocarbons
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
physiological role is the inactivation of catecholamine hormones and neurotransmitters as well as detoxification of a variety of xenobiotic amines and drugs
-
-
?
additional information
?
-
-
not: monophenols
-
-
?
additional information
?
-
-
not: monophenols
-
-
?
additional information
?
-
-
strict requirement for S-adenosyl-L-methionine as methyl donor and a catechol as acceptor substrate
-
-
?
additional information
?
-
-
physiological role is the inactivation of catecholamine hormones and neurotransmitters as well as detoxification of a variety of xenobiotic amines and drugs
-
-
?
additional information
?
-
-
membrane protein and (or) lipid components may play an important role in catecholamine metabolism
-
-
?
additional information
?
-
-
primary role in extraneuronal inactivation of endogenous catecholamines and in the further metabolism of oxidized catecholamine metabolites
-
-
?
additional information
?
-
-
COMT in the adrenal gland might not be related to blood pressure regulation
-
-
?
additional information
?
-
-
degree and position of methylation depend clearly on the three-dimensional structure of the entire substrate molecule
-
-
?
additional information
?
-
-
slight activity on orcinol, caffeic acid, and pyrogallol. No substrates: guaiacol, salicylic acid, benzoic acid, 2,5-dimethyl-4-methoxy-3(2H)-furanone
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
benzimidazole
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-epicatechin-3-gallate
-
IC50: 0.0002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0003 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin
-
IC50: 0.044 mM with 2-hydroxyestradiol as substrate, IC50: 0.05 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-4''-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-7-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin-3-gallate
(-)-epigallocatechin-3-gallate-3''-O-glucuronide
-
IC50: 0.002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0025 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-3'-O-glucuronide
-
IC50: 0.0018 mM with 2-hydroxyestradiol as substrate, IC50: 0.0023 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-4''-O-glucuronide
-
IC50: 0.0025 mM with 2-hydroxyestradiol as substrate, IC50: 0.004 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-7-O-glucuronide
-
IC50: 600 nM with 2-hydroxyestradiol as substrate, IC50: 800 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-O-gallate
(-)epicatechin
-
IC50: 0.06 mM with 2-hydroxyestradiol as substrate, IC50: 0.08 mM with 4-hydroxyestradiol as substrate
(-)epicatechin gallate3,5-dinitrocatechol
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(2-amino-3-methylbutanoyloxy)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
-
(2R,3R)-5,7-bis(acetyloxy)-2-[3,4,5-tris(acetyloxy)phenyl]-3,4-dihydro-2H-chromen-3-yl 3,4-bis(acetyloxy)-5-(2-oxopropyl)benzoate
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,4,5-trihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,4,5-tris(acetyloxy)benzoate]
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,5-bis(acetyloxy)benzoate]
-
-
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
-
uncompetitive inhibitor of the sCOMT isoform
1-(4-butylphenyl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-(butyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-(isobutyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-([1,1'-biphenyl]-3-yl)-3-hydroxypyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxy-2-methylpropyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxybutyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-methylpyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-phenylpyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-[hydroxy(phenyl)methyl]pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-4-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-Carboxysalsoline
-
i.e. 1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
-
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
13-hydroxy-36-(trifluoromethyl)-14H-[11,22:24,32-terpyridin]-14-one
-
2-Hydroxyestradiol-17beta 3-methyl ether
-
product inhibition
2-methoxyestradiol-17beta
-
product inhibition
3,4,5-trihydroxypyrogallol
-
liver homogenate, 0.03 mM inhibitor: 0.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3,4-dihydroxymethamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
3-chloro-5,6-dihydroxy-7-nitro-1-benzothiophene-2-carboxylic acid
-
-
3-fluoro-4-[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 32.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-hydroxy-4'-phenyl-4H-[1,2'-bipyridin]-4-one
potent inhibitor with sufficient in vivo exposure to significantly affect the dopamine metabolites homovanillic acid and dihydroxyphenylacetic acid
3-nitro-5-(1-p-tolyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4''-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4',3'',4''-tri-O-methyl epigallocatechin gallate
-
substrate: epigallocatechin
4',4''-di-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4'-(1-benzyl-1H-pyrazol-4-yl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
-
4'-(3,4-dichlorophenyl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
-
4'-4''-di-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.00015 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate, competitive with respect S-adenyosylmethionine, noncompetitive with respect to catechol
4'-fluoro-3-hydroxy-5'-phenyl-4H-[1,3'-bipyridin]-4-one
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-O-methyl-(-)-epigallocatechin
-
IC50: 0.032 mM with 2-hydroxyestradiol as substrate, IC50: 0.04 mM with 4-hydroxyestradiol as substrate
4'-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.0001 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
4-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2,3-triol
-
liver homogenate, 0.03 mM inhibitor: 26.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)benzonitrile
-
liver homogenate, 0.003 mM inhibitor: 0.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(tert-octyl)phenol
-
causes significant inhibition of enzyme activity
4-hydroxyequilenin
-
inhibits its own methylation by COMT at higher concentrations in the presence of the reducing agent dithiothreitol, irreversible inhibitor, the inhibitor causes formation of intermolecular disulfide bonds, cys33 in recombinant human soluble COMT is the residue most likely modified by the inhibitor
4-phenyl-7,8-dihydroxycoumarin
-
4-[1-(4-methylphenyl)-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 41.2% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-[4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,2,3-triol
-
liver homogenate, 0.003 mM inhibitor: 15.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-(1-methyl-1H-pyrazol-5-yl)-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 1.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-(cyclopentylsulfonyl)-7-fluoroquinolin-8-ol
compound displays good pharmacokinetics in rats. pIC50 value 8.7 for membrane-bound form, 5.6 for soluble form
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
5-hydroxy-2-(thiophen-2-yl)pyrimidin-4(1H)-one
-
5-Substituted 3-hydroxy-4-methoxybenzaldehydes
-
-
5-Substituted 3-hydroxy-4-methoxybenzoic acids
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
-
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-2,3-dihydroxybenzoic acid
-
liver homogenate, 0.03 mM inhibitor: 24.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-4-phenyl-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 68.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
7-chloro-5-((4-fluorophenyl)sulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies. pIC50 value 6.7 for membrane-bound form, below 5 for soluble form
7-chloro-5-(cyclopentylsulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies. pIC50 value 7.7 for membrane-bound form, below 5 for soluble form
7-chloro-5-(pyrrolidin-1-ylsulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies . pIC50 value 8.0 for membrane-bound form, 5.5 for soluble form
7-fluoro-5-(pyrrolidin-1-ylsulfonyl)quinolin-8-ol
compound displays good pharmacokinetics in rats. pIC50 value 8.4 for membrane-bound form, 5.8 for soluble form
8-O-methyldaphnetin
0.1 mM, about 20% residual activity. 8-O-methyldaphnetin has no effect on Km but decreases Vmax
9-hydroxypyrido[2,1-c][1,4]benzothiazin-8(6H)-one
-
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
-
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
-
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
amino group reagents
-
-
-
Analogs of S-adenosyl-L-homocysteine
-
overview: inhibition of the liver, heart and brain enzyme
benzyl butyl phthalate
-
causes significant inhibition of enzyme activity
benzyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
beta-thujaplicin
-
70-100% inhibition at 0.2 mM
butyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
butyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
caffeic acid phenethyl ester
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C
chlorogenic acid
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C
chrysin
-
slight inhibition at 0.3 mM
Cistus parviflorus leaf extract
-
mixed type inhibition
-
daidzein
-
soy isoflavones at hormonally active concentrations cause a significant reduction of both COMT mRNA levels and COMT activity as well as of the methylation of 4-hydroxyestradiol
daphnetin
0.1 mM, about 10% residual activity
dibutyl phthalate
-
causes significant inhibition of enzyme activity
dihydromyricetin
-
competitive
diisononyl phthalate
-
causes significant inhibition of enzyme activity
dioctyl phthalate
-
causes significant inhibition of enzyme activity
dobutamine
-
competitive to dopamine
dopamine
-
competitive to dobutamine
epigallocatechin-3-gallate
-
inhibition in vitro. Supplementation with a high dose does not impair the activity of COMT
Fe3+
quantum mechanical/molecular mechanical dynamics study
flavone
-
IC50: 0.00549 mM
flavonoids
-
overview: relationship between structure and ability to inhibit
Gallic acid methylester
-
-
Hg2+
-
complete inhibition at 1 mM
high ionic strength
-
-
-
isobutyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
isopropyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
lactoferrin
bovine lactoferrin binds to and inhibits COMT using its N-terminal region. A fragment of the lactoferrin N-terminal residues 6-50, with two pairs of disulfide bonds, shows higher inhibitory activity than intact lactoferrin. Lactoferrin does not compete with S-adenosylmethionine. COMT activity in the cell extracts form Caco-2 and HepG2 cells is inhibited by lactoferrin and the N-terminal fragment
-
methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
N-(2-[2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethoxy]-ethyl)-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 0.002 mM
N-(3,4-Dihydroxyphenyl)maleimide
-
irreversible
N-(3,4-Dihydroxyphenyl)succinimide
-
reversible
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-ethyl-3,4-dihydroxyamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
-
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(E)-4-[(2R,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-but-2-enyl]-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 9 nM
N-[2-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]ethyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 60 nM
N-[3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]propyl]2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 200 nM
N-[4-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]butyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.005 mM
N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.09 mM, very potent bisubstrate inhibitor
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
-
nordihydroguaiaretic acid
-
-
norepinephrine
-
0.01 mM, 41% inhibition of 2-hydroxyestradiol methylation
OR-462
-
disubstituted catechol
OR486
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
p-hydroxymercuribenzoate
-
70-100% inhibition at 0.2 mM
Peganum harmala seed extract
-
mixed type inhibition
-
Polyphenolic compounds
-
-
-
propyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
purpurogallin carboxylic acid
-
-
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
-
S-adenosyl-L-homocysteine
S-adenosyl-L-methionine
-
-
salvianolic acid B
-
weak inhibitor. In vivo, a single intravenous dose of salvianolic acid B decreases the plasma concentration of 3-O-methyldopa, with no obvious effect on the pharmacokinetics of L-dopa
theaflavin-3,3'-digallate
-
decreased Vmax and increased Km-value
Vitex agnus-cactus leaf extract
-
mixed type inhibition
-
[5-(3,4-dihydroxy-5-nitrophenyl)-4-phenyl-1H-pyrazol-1-yl](4-methylphenyl)methanone
-
liver homogenate, 0.003 mM inhibitor: 2.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
(-)-epigallocatechin-3-gallate
-
IC50: 70 nM with 2-hydroxyestradiol as substrate, IC50: 80 nM with 4-hydroxyestradiol as substrate, mixed inhibitor
(-)-epigallocatechin-3-gallate
-
-
(-)-epigallocatechin-3-O-gallate
-
IC50: 0.05-0.07 nM for the O-methylation of 2-hydroxyestradiol, IC50: 200-500 nM for O-methylation of 4-hydroxyestradiol
(-)-epigallocatechin-3-O-gallate
potent non-competitive inhibitor
(-)-epigallocatechin-3-O-gallate
-
-
(-)-epigallocatechin-3-O-gallate
potent non-competitive inhibitor
(-)-epigallocatechin-3-O-gallate
-
potent non-competitive inhibitor
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
-
-
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
-
-
3,5-dinitrocatechol
-
liver S-COMT, 50% inhibition at 74 nM
3,5-dinitrocatechol
-
uncompetitive inhibitor
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
-
-
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
-
-
Ca2+
-
-
Ca2+
quantum mechanical/molecular mechanical dynamics study
caffeic acid
-
-
caffeic acid
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C
catechin
-
IC50: 14-17 nM for the O-methylation of 2-hydroxyestradiol, IC50: 0.005-0.007 mM for O-methylation of 4-hydroxyestradiol
catechin
-
IC50: 0.00164 mM
entacapone
-
-
entacapone
0.001 mM, about 10% residual activity
epicatechin
-
IC50: 44-65 nM for the O-methylation of 2-hydroxyestradiol, IC50: 0.01-0.018 mM for O-methylation of 4-hydroxyestradiol
epicatechin
-
IC50: 0.00196 mM
epigallocatechin
-
fisetin
-
IC50: 0.0033-0.0045 nM for the O-methylation of 2-hydroxyestradiol, IC50: 0.0026-0.0042 nM for O-methylation of 4-hydroxyestradiol
gallic acid
-
-
genistein
-
slight inhibition at 0.3 mM
genistein
-
soy isoflavones at hormonally active concentrations cause a significant reduction of both COMT mRNA levels and COMT activity as well as of the methylation of 4-hydroxyestradiol
iodoacetic acid
-
-
L-ascorbic acid
-
-
L-Dopa
-
-
Mg2+
-
required for activity
Mg2+
-
required for activity
Mg2+
-
required for activity
Mg2+
-
inhibition above 2 mM; required for activity
Mg2+
-
required for activity
N-ethylmaleimide
-
-
N-ethylmaleimide
-
70-100% inhibition at 0.2 mM
N-ethylmaleimide
-
complete inhibition at 1 mM
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
-
p-chloromercuribenzoate
-
complete inhibition at 1 mM
purpurogallin
-
-
purpurogallin
-
decreased Vmax and increased Km-value
pyrogallol
-
-
pyrogallol
-
70-100% inhibition at 0.2 mM
quercetin
-
IC50: 0.0085 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
quercetin
-
IC50: 0.0009-0.0015 mM for the O-methylation of 2-hydroxyestradiol, IC50: 0.0005-0.0012 mM for O-methylation of 4-hydroxyestradiol
quercetin
-
IC50: 0.00048 mM
quercetin
-
0.01 mM, 90% inhibition of 2-hydroxyestradiol methylation
Ro 41-0960
-
-
Ro 41-0960
-
IC50: 5-42 nM
Ro41-0960
-
blocks the methoxylation of catechol estrogens, with concomitant 3fold to 4fold increases in the levels of the depurinating adducts. Low activity of COMT leads to higher levels of depurinating estrogen-DNA adducts that can induce mutations and initiate cancer
Ro41-0960
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
S-adenosyl-L-homocysteine
-
-
S-adenosyl-L-homocysteine
-
-
S-adenosyl-L-homocysteine
-
50% inhibition at about 0.005 mM
S-adenosyl-L-homocysteine
-
-
Salsolidine
-
i.e. 1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
tolcapone
-
-
tolcapone
-
possibility of genotype-targeted pharmacology for the treatment of cognitive dysfunction associated with schizophrenia. Even though tolcapone has proved useful in this regard, its hepatotoxicity proscribes its wide-spread use. The development of COMT inhibitors that can permeate the blood-brain barrier effectively and are devoid of serious adverse effects will allow expansion of the search for more specific, selective and effective therapies for the treatment of cognitive disorders
tolcapone
-
inhibitor of isoform MB-COMT, substrate of isoform S-COMT
tolcapone
-
tolcapone increases significantly the cytotoxic effect of high dose UVB irradiation in HaCat cells. High concentrations of tolcapone reduce melanin levels in melanoma cells parallel to reduced cell numbers
tolcapone
-
strongly inhibits the formation of 3-methylsalvianolic acid B in vitro and in vivo, without any change in its plasma concentration. Tolcapone significantly increases the cumulative bile excretion of salvianolic acid from 3% to 40% in the rat
tropolone
-
-
tropolone
-
complete inhibition at 0.25 mM
tropolone
-
70-100% inhibition at 0.2 mM
U-0521
-
-
additional information
-
COMT activity appears unaffected by loss of the dopaminergic nigrostriatal pathway and levodopa treatment
-
additional information
-
substrate inhibition is dependent on the concentration of S-adenosylmethionine and MgCl2
-
additional information
-
activity of the enzyme is strongly influenced by the nature of the buffer
-
additional information
-
no inhibition by genistein, daidzein and biochanin A
-
additional information
-
role of COMT inhibitors in Parkinsons disease as a new therapeutic approach to Parkinsons disease involving conversion of levodopa to dopamine at the target region in the brain and facilitation of the continuous action of this amine at the receptor sites. A historical overview of the discovery and development of COMT inhibitors is presented with a special emphasis on nebicapone, presently under clinical development, as well as entacapone and tolcapone, which are already approved as adjuncts in the therapy of Parkinsons disease. This article reviews human pharmacokinetic and pharmacodynamic properties of these drugs as well as their clinical efficacy and safety
-
additional information
-
(-)-epigallocatechin is not active even at a concentration of 0.05 mM
-
additional information
-
inhibition by analogs of S-adenosyl-homcysteine
-
additional information
-
relationship between the structure of flavonoids and their inhibitory activity
-
additional information
COMT is a target for inhibitor development aiming at Parkinsons disease treatment and is submitted to extensive structure-based drug design
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00032 - 0.00037
(-)-epigallocatechin-3-gallate
0.000006
(2-amino-3-methylbutanoyloxy)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.007022
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0000016
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000166
1-(butyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.000017
1-(isobutyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.44
1-Carboxysalsoline
-
-
0.004645
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.014
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0749
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000019
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
0.0000456
3,5-dinitrocatechol
-
pH 7.4, 37°C
0.000001
3-chloro-5,6-dihydroxy-7-nitro-1-benzothiophene-2-carboxylic acid
-
Ki value below 0.000001 mM, pH not specified in the publication, temperature not specified in the publication
0.026
4-hydroxyequilenin
-
pH 7.8, inhibition og methylation of 4-hydroxyestradiol
0.0024
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.002378
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000001
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.025
8-O-methyldaphnetin
pH 7.4, 37°C
0.000034
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0000102
benzyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000013
butyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000106
butyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.000037
daphnetin
pH 7.4, 37°C
0.0009
dihydromyricetin
-
37°C, pH not specified in the publication
0.000017
isobutyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000011
isopropyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0000022
methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.0002
myricetin
-
37°C, pH not specified in the publication
0.0005
Myricitrin
-
37°C, pH not specified in the publication
0.0104
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0156
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0199
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000002
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000007
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000007
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0000092
propyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
pH not specified in the publication, temperature not specified in the publication
0.000132
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.001 - 0.04
S-adenosyl-L-homocysteine
0.0021
salvianolic acid B
-
37°C, pH not specified in the publication
0.005
tropolone
-
plus dopamine
0.00032
(-)-epigallocatechin-3-gallate
-
substrate: 2-hydroxyestradiol
0.00037
(-)-epigallocatechin-3-gallate
-
substrate: 4-hydroxyestradiol
0.0053
RO-4-4602
-
plus norepinephrine
0.007
RO-4-4602
-
plus dopamine
0.009
RO-4-4602
-
plus epinephrine
0.001
S-adenosyl-L-homocysteine
-
cosubstrate S-adenosyl-L-methionine
0.007
S-adenosyl-L-homocysteine
-
cosubstrate S-adenosyl-L-methionine
0.022 - 0.04
S-adenosyl-L-homocysteine
-
-
0.039
S-adenosyl-L-homocysteine
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.0003
(-)-epicatechin-3-gallate
Homo sapiens
-
IC50: 0.0002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0003 mM with 4-hydroxyestradiol as substrate
0.044 - 0.05
(-)-epigallocatechin
0.00007 - 0.00008
(-)-epigallocatechin-3-gallate
0.0025
(-)-epigallocatechin-3-gallate-3''-O-glucuronide
Homo sapiens
-
IC50: 0.002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0025 mM with 4-hydroxyestradiol as substrate
0.0023
(-)-epigallocatechin-3-gallate-3'-O-glucuronide
Homo sapiens
-
IC50: 0.0018 mM with 2-hydroxyestradiol as substrate, IC50: 0.0023 mM with 4-hydroxyestradiol as substrate
0.004
(-)-epigallocatechin-3-gallate-4''-O-glucuronide
Homo sapiens
-
IC50: 0.0025 mM with 2-hydroxyestradiol as substrate, IC50: 0.004 mM with 4-hydroxyestradiol as substrate
0.0006 - 0.0008
(-)-epigallocatechin-3-gallate-7-O-glucuronide
0.00004 - 0.0017
(-)-epigallocatechin-3-O-gallate
0.08
(-)epicatechin
Homo sapiens
-
IC50: 0.06 mM with 2-hydroxyestradiol as substrate, IC50: 0.08 mM with 4-hydroxyestradiol as substrate
0.0316
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.029
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate)
Homo sapiens
-
70-79% inhibition at 0.025-0.05 mM
0.3
1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.00016
1-(4-butylphenyl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.000047 - 0.0011
1-([1,1'-biphenyl]-3-yl)-3-hydroxypyridin-4(1H)-one
0.00018 - 0.0019
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxy-2-methylpropyl)pyridin-4(1H)-one
0.00057 - 0.001
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxybutyl)pyridin-4(1H)-one
0.000099 - 0.0014
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
0.00014
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.000053 - 0.0021
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-methylpyridin-4(1H)-one
0.00087 - 0.0025
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-phenylpyridin-4(1H)-one
0.000088 - 0.0013
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-[hydroxy(phenyl)methyl]pyridin-4(1H)-one
0.00014
1-([1,1'-biphenyl]-4-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0209
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0628
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.336
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0000265 - 0.000881
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
0.0000274 - 0.000237
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
0.000084
13-hydroxy-36-(trifluoromethyl)-14H-[11,22:24,32-terpyridin]-14-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.2
3,4-dihydroxymethamphetamine
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.00004418
3,5-dinitrocatechol
Sus scrofa domesticus
-
pH 7.4, 37°C
0.00004 - 0.00302
3-hydroxy-4'-phenyl-4H-[1,2'-bipyridin]-4-one
0.0000495
4'-(1-benzyl-1H-pyrazol-4-yl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.000035
4'-(3,4-dichlorophenyl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.00015
4'-4''-di-O-methyl-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 0.00015 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate, competitive with respect S-adenyosylmethionine, noncompetitive with respect to catechol
0.000055 - 0.000946
4'-fluoro-3-hydroxy-5'-phenyl-4H-[1,3'-bipyridin]-4-one
0.001368
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.001858
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.04
4'-O-methyl-(-)-epigallocatechin
Homo sapiens
-
IC50: 0.032 mM with 2-hydroxyestradiol as substrate, IC50: 0.04 mM with 4-hydroxyestradiol as substrate
0.0001
4'-O-methyl-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 0.0001 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
0.000013 - 0.000565
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
0.00086
5-hydroxy-2-(thiophen-2-yl)pyrimidin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0108
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0107
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000006
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0004
9-hydroxypyrido[2,1-c][1,4]benzothiazin-8(6H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.000011
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000025
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000155
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.00196 - 0.068
epicatechin
0.006 - 0.048
epigallocatechin
0.00549
flavone
Homo sapiens
-
IC50: 0.00549 mM
0.00457
Harmaline
Sus scrofa domesticus
-
pH 7.4, 37°C
0.01319
harmalol
Sus scrofa domesticus
-
pH 7.4, 37°C
0.002
N-(2-[2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethoxy]-ethyl)-2,3-dihydroxy-5-nitro-benzamide
Homo sapiens
-
IC50: 0.002 mM
0.0468
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.1
N-ethyl-3,4-dihydroxyamphetamine
Homo sapiens
-
isoform sCOMT, in phosphate buffer (pH 7.4)
0.0703
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.0895
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000011
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000026
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
0.000031 - 0.000035
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
0.000236
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000082
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000043
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.028
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.00004
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000009
N-[(E)-4-[(2R,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-but-2-enyl]-2,3-dihydroxy-5-nitro-benzamide
Homo sapiens
-
IC50: 9 nM
0.00006
N-[2-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]ethyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 60 nM
0.0002
N-[3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]propyl]2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 200 nM
0.005
N-[4-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]butyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 0.005 mM
0.09
N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
Homo sapiens
-
IC50: 0.09 mM, very potent bisubstrate inhibitor
0.000032
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000596
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.00048 - 0.0085
quercetin
0.000005 - 0.000042
Ro 41-0960
Homo sapiens
-
IC50: 5-42 nM
0.0000067
tolcapone
Homo sapiens
-
isoform MB-COMT, pH 7.4, 37°C
0.044
(-)-epigallocatechin
Homo sapiens
-
IC50: 0.044 mM with 2-hydroxyestradiol as substrate,
0.05
(-)-epigallocatechin
Homo sapiens
-
IC50: 0.05 mM with 4-hydroxyestradiol as substrate
0.00007
(-)-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 70 nM with 2-hydroxyestradiol as substrate
0.00008
(-)-epigallocatechin-3-gallate
Homo sapiens
-
IC50: 80 nM with 4-hydroxyestradiol as substrate, mixed inhibitor
0.0006
(-)-epigallocatechin-3-gallate-7-O-glucuronide
Homo sapiens
-
IC50: 600 nM with 2-hydroxyestradiol as substrate
0.0008
(-)-epigallocatechin-3-gallate-7-O-glucuronide
Homo sapiens
-
IC50: 800 nM with 4-hydroxyestradiol as substrate
0.00004 - 0.00007
(-)-epigallocatechin-3-O-gallate
Homo sapiens
-
IC50: 0.04-0.07 microM for the O-methylation of 2-hydroxyestradiol
0.00007
(-)-epigallocatechin-3-O-gallate
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.00037 - 0.00046
(-)-epigallocatechin-3-O-gallate
Homo sapiens
-
IC50: 0.37-0.46 microM for O-methylation of 4-hydroxyestradiol
0.00054
(-)-epigallocatechin-3-O-gallate
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.0012
(-)-epigallocatechin-3-O-gallate
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0012
(-)-epigallocatechin-3-O-gallate
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0015
(-)-epigallocatechin-3-O-gallate
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.0017
(-)-epigallocatechin-3-O-gallate
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.000047
1-([1,1'-biphenyl]-3-yl)-3-hydroxypyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0011
1-([1,1'-biphenyl]-3-yl)-3-hydroxypyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.00018
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxy-2-methylpropyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0019
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxy-2-methylpropyl)pyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.00057
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxybutyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.001
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxybutyl)pyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.000099
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0014
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.000053
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-methylpyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0021
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-methylpyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.00087
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-phenylpyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0025
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-phenylpyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.000088
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-[hydroxy(phenyl)methyl]pyridin-4(1H)-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.0013
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-[hydroxy(phenyl)methyl]pyridin-4(1H)-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.0000265
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.0000449
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Homo sapiens
-
isoform MB-COMT, pH 7.4, 37°C
0.000857
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Homo sapiens
-
isoform S-COMT, pH 7.4, 37°C
0.000881
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
0.0000274
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.000039
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
-
isoform MB-COMT, pH 7.4, 37°C
0.000226
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
-
isoform S-COMT, pH 7.4, 37°C
0.000237
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
0.00004
3-hydroxy-4'-phenyl-4H-[1,2'-bipyridin]-4-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.00302
3-hydroxy-4'-phenyl-4H-[1,2'-bipyridin]-4-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.000055
4'-fluoro-3-hydroxy-5'-phenyl-4H-[1,3'-bipyridin]-4-one
Homo sapiens
membrane-bound isoform, pH not specified in the publication, temperature not specified in the publication
0.000946
4'-fluoro-3-hydroxy-5'-phenyl-4H-[1,3'-bipyridin]-4-one
Homo sapiens
soluble isoform, pH not specified in the publication, temperature not specified in the publication
0.000013
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform MB-COMT, pH 7.4, 37°C
0.000063
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
-
isoform MB-COMT, pH 7.4, 37°C
0.000175
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Homo sapiens
-
isoform S-COMT, pH 7.4, 37°C
0.000565
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
Rattus norvegicus
-
isoform S-COMT, pH 7.4, 37°C
0.00164
catechin
Homo sapiens
-
IC50: 0.00164 mM
0.005 - 0.007
catechin
Homo sapiens
-
IC50: 14-17 nM for the O-methylation of 2-hydroxyestradiol, IC50: 0.005-0.007 mM for O-methylation of 4-hydroxyestradiol
0.0066
catechin
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.008
catechin
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.012
catechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0153
catechin
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.016
catechin
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.019
catechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.00196
epicatechin
Homo sapiens
-
IC50: 0.00196 mM
0.01 - 0.018
epicatechin
Homo sapiens
-
IC50: 44-65 nM for the O-methylation of 2-hydroxyestradiol, IC50: 0.01-0.018 mM for O-methylation of 4-hydroxyestradiol
0.015
epicatechin
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.019
epicatechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.04
epicatechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0532
epicatechin
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.062
epicatechin
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.068
epicatechin
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.006
epigallocatechin
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.015
epigallocatechin
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.02
epigallocatechin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.022
epigallocatechin
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.039
epigallocatechin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.048
epigallocatechin
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.0021
fisetin
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.0021
fisetin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0026 - 0.0042
fisetin
Homo sapiens
-
IC50: 0.0026-0.0042 mM for O-methylation of 4-hydroxyestradiol
0.0032
fisetin
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.0033 - 0.0045
fisetin
Homo sapiens
-
IC50: 0.0033-0.0045 mM for the O-methylation of 2-hydroxyestradiol
0.0035
fisetin
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.0035
fisetin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0043
fisetin
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000009
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000031
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
-
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.000035
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
Rattus norvegicus
liver homogenate, substrate benzene-1,2-diol, pH 7.6, 37°C
0.00048
quercetin
Homo sapiens
-
IC50: 0.00048 mM
0.0005 - 0.0012
quercetin
Homo sapiens
-
IC50: 0.0009-0.0015 mM for the O-methylation of 2-hydroxyestradiol, IC50: 0.0005-0.0012 mM for O-methylation of 4-hydroxyestradiol
0.0009
quercetin
Homo sapiens
O-methylation of 4-hydroxyestradiol
0.0012
quercetin
Homo sapiens
O-methylation of 2-hydroxyestradiol
0.0021
quercetin
Sus scrofa
-
O-methylation of 4-hydroxyestradiol
0.0022
quercetin
Rattus norvegicus
O-methylation of 4-hydroxyestradiol
0.0039
quercetin
Sus scrofa
-
O-methylation of 2-hydroxyestradiol
0.0045
quercetin
Rattus norvegicus
O-methylation of 2-hydroxyestradiol
0.0085
quercetin
Homo sapiens
-
IC50: 0.0085 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.